|1.||Aberrant Crypt Foci
|4.||Hypoprothrombinemias (Prothrombin Deficiency)
|5.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
|1.||Darnige, Luc: 2 articles (04/2015 - 04/2007)|
|2.||Witte, David P: 2 articles (06/2014 - 12/2002)|
|3.||Lancellotti, Stefano: 2 articles (09/2013 - 06/2009)|
|4.||De Cristofaro, Raimondo: 2 articles (09/2013 - 06/2009)|
|5.||Hollon, W: 1 article (11/2015)|
|6.||Rajpurkar, M: 1 article (11/2015)|
|7.||Roy, S: 1 article (11/2015)|
|8.||Sarker, T: 1 article (11/2015)|
|9.||Mulliez, S M N: 1 article (06/2015)|
|10.||Vantilborgh, A: 1 article (06/2015)|
|1.||Warfarin (Coumadin)FDA LinkGeneric
02/01/2003 - "Warfarin-associated hypoprothrombinemia: an unusual presentation."
09/01/1987 - "Both the hypoprothrombinemia (P less than 0.001) and plasma warfarin concentrations (P less than 0.01) were significantly increased. "
01/01/1982 - "Both the hypoprothrombinemia (p less than 0.001) and the plasma warfarin concentrations (p less than 0.05) were significantly augmented. "
12/01/1981 - "Six subjects received 300 mg orally of phenybutazone daily, beginning 3 days before warfarin and continuing throughout hypoprothrombinemia. "
10/01/1977 - "Influence of 3,4-benzo(a)pyrene on warfarin hypoprothrombinemia and disposition in the rat."
|2.||Prothrombin (Factor II)IBA
05/01/1994 - "The hypoprothrombinemia in this syndrome is the result of rapid clearance of prothrombin-antiprothrombin antibody complexes by the reticulo-endothelial system. "
01/15/1990 - "The prothrombin survival time indicates that the hypoprothrombinemia is due to the clearance of the prothrombin-antiprothrombin complex in vivo."
12/01/2000 - "In this study, 13 patients with prothrombin deficiency were screened for the presence of alterations in the prothrombin gene, and nine novel candidate mutations were identified. "
11/01/1947 - "Clinical hypoprothrombinemia; a study of factors A and B of prothrombin."
09/01/2013 - "Two novel mutations in the prothrombin gene identified in a patient with compound heterozygous type 1/2 prothrombin deficiency."
|3.||Vitamin K 1 (Phylloquinone)FDA LinkGeneric
01/01/1959 - "Efficacy of water-soluble derivatives of vitamin K1 in counteracting drug-induced hypoprothrombinemia."
11/01/1959 - "[A new study on the therapeutic action of vitamin K1 on hypoprothrombinemia in the premature infant]."
01/01/2010 - "Vitamin K1 is frequently used in the treatment and prevention of hypoprothrombinemia and hemorrhagic disease of the newborn. "
07/01/1963 - "Drug-induced hypoprothrombinemia countered with phytonadione."
04/01/1962 - "Oral vitamin K 1 (phytonadione) as prophylaxis for hypoprothrombinemia in full-term and premature infants."
|4.||Sulfinpyrazone (Anturane)FDA Link
01/01/1986 - "Concomitant sulfinpyrazone dosing markedly increased hypoprothrombinemia, decreased clearance of (S)-warfarin, and increased clearance of (R)-warfarin. "
01/01/1982 - "Thus, sulfinpyrazone augmented the hypoprothrombinemia of racemic warfarin stereoselectively by reduced metabolic clearance of S-warfarin. "
09/01/1987 - "Sulfinpyrazone treatment did not affect the hypoprothrombinemia produced by phenprocoumon nor did it significantly alter the plasma elimination kinetics of the individual (R)- and (S)-enantiomers. "
01/01/1982 - "R-warfarin with sulfinpyrazone did not significantly change the hypoprothrombinemia but significantly (p less than 0.05) reduced warfarin concentrations. "
01/01/1982 - "S-warfarin with sulfinpyrazone caused a highly significant augmentation of both the hypoprothrombinemia (p less than 0.001) and the plasma warfarin concentrations (p less than 0.001). "
|5.||Dicumarol (Dicoumarol)FDA Link
07/01/1960 - "Dihydrovitamin Kl biphosphate in bishydroxycoumarin induced hypoprothrombinemia."
01/01/1960 - "Effect of bishydroxycoumarin (Dicumarol) and hypoprothrombinemia upon cerebral hemodynamics."
09/01/1957 - "Relation between duration of hypoprothrombinemia with dicumarol and the level of the drug in the liver."
03/01/1952 - "[Effects of vitamine K 1 on hypoprothrombinemia caused by dicumarol and on the acceleration factors in the rabbit with liver damage and the hepatectomized cat]."
10/01/1951 - "Hypoprothrombinemia due to dicumarol in a malingerer: a case report."
|6.||Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA
11/01/1994 - "Reevaluation 2 months later showed that the lupus anticoagulant had disappeared and the prothrombin deficiency was markedly improved. "
06/01/2015 - "Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature."
11/01/2013 - "Cerebral microbleeds in lupus anticoagulant-hypoprothrombinemia syndrome."
03/01/2013 - "Hypoprothrombinemia associated with a lupus anticoagulant (LA) was first reported in the literature over 50 years ago. "
09/01/2012 - "Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature."
|7.||Vitamin K 2 (Vitamin K2)IBA
08/01/1984 - "coli and Bacteroides fragilis, organisms that are major producers of bacterially synthesized menaquinones, was associated with a high incidence of hypoprothrombinemia. "
07/01/1982 - "The effects of vitamin K2 syrup on neonatal hypoprothrombinemia--double blind study."
12/30/2005 - "Vitamin K2 (VK2), which has been in wide use for the management of hypoprothrombinemia and osteoporosis in Japan, was tested for its efficacy on experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). "
01/01/1952 - "[Hypoprothrombinemia secondary to dicoumarin therapy; shock due to prolonged vitamin K2 therapy and perfusions and spectacular cure with vitamin K1]."
06/01/1985 - "This suggests that non-neutralizing antibodies to prothrombin cause plasma prothrombin deficiency because of a rapid clearance of prothrombin-antibody complexes, which is slowed by adrenal corticosteroids. "
01/01/1999 - "Both patients were diagnosed with lupus anticoagulant-hypoprothrombinemia syndrome (LAC-HPS) as a result of non-neutralizing antibodies directed against Factor II. LAC-HPS is a rare clinical entity that can occur in association with SLE, transient viral infections, drug reactions or even in healthy individuals. "
|9.||Ticrynafen (Tienilic Acid)IBA
09/01/1982 - "Thus, ticrynafen probably augments the hypoprothrombinemia of racemic warfarin by reducing metabolic clearance of S-warfarin. "
09/01/1982 - "To examine the ticrynafen-warfarin interaction, normal subjects received large single doses of 1.5 mg/kg racemic warfarin with and without daily oral doses of 250 mg ticrynafen beginning 3 days before warfarin and continuing for the duration of hypoprothrombinemia. "
08/15/1983 - "Ticrynafen administration enhanced the degree of hypoprothrombinemia and altered plasma and hepatic vitamin K epoxide concentrations in warfarin-treated rats. "
|10.||Secobarbital (Sebar)FDA Link
08/01/1980 - "It was concluded that secobarbital diminished the hypoprothrombinemia of pseudoracemic warfarin by increasing plasma clearance of the more hypoprothrombinemic S-warfarin and by increasing plasma clearance of the less hypoprothombinemic R-warfarin."
08/01/1980 - "There was a reduction of the hypoprothrombinemia of the pseuoracemate during the secobarbital regimen over that on warfarin alone (p < 0.001). "
08/01/1980 - "It was given with and without a daily oral dose of secobarbital, 100 mg, beginning 7 days before the warfarin and continuing throughout the hypoprothrombinemia. "
|2.||Prostheses and Implants (Prosthesis)
|4.||Infant Equipment (Crib)
08/01/2001 - "Concerning care in the delivery room, we stress the importance of care of the newborn (especially of the umbilical cord), bonding between the mother and child, identification of the newborn, assessment of neonatal adaptation to extrauterine life, prevention of ophthalmia neonatorum and hypoprothrombinemia, placing the baby correctly in the crib and hepatitis B prophylaxis. "
|5.||Tooth Extraction (Tooth Extractions)